articleThe Lancet OncologyNov 15, 2012GREEN OA

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

JBJaafar BennounaJSJavier SastreDADirk ArnoldPÖPia ÖsterlundRGRichard Greil

Institut de Cancérologie de l'Ouest · Hospital Clínico San Carlos · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,163
total citations
FWCI
54.57
Percentile
100%
References
30
Citations per year

Authors

17

Topics & keywords

Topics
Keywords
  • Bevacizumab
  • Medicine
  • Irinotecan
  • Oxaliplatin
  • Chemotherapy
  • Colorectal cancer
  • Clinical endpoint
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding